Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence

Core Insights - Bristol Myers Squibb has signed an agreement with Evinova to optimize clinical trials using Evinova's AI-native clinical development platform, specifically the Cost Optimizer module [1][2] - The partnership aims to enhance decision-making, identify productivity opportunities, and create more efficient trial designs to accelerate innovation and improve experiences for sites and patients [2][3] Evinova's AI-Native Platform - Evinova's platform utilizes agentic AI to enhance study design, streamline processes, and ensure seamless digital data flow in compliance with USDM standards [4] - The platform has delivered hundreds of millions of dollars in multi-year savings for customers, showcasing its effectiveness in clinical development [4] Unified Trial Solution - Evinova's Unified Trial Solution integrates essential study elements to create a connected trial experience for sponsors, sites, and patients, incorporating eCOA with telehealth and remote patient monitoring [5] - This solution aims to improve data collection for novel endpoints and innovative trial designs while reducing friction points [5] Proven Outcomes - Evinova's solutions have demonstrated significant improvements, including up to 60% enhancement in patient experience, a 6-month acceleration in trial delivery, and a 32% reduction in costs [8][9] - The platform is designed to accelerate timelines, reduce costs, improve data quality, and enhance patient experiences [6]